title: Blood pressure augmentation and maternal circulating concentrations of angiogenic factors at delivery in preeclamptic and uncomplicated pregnancies.
abstract: OBJECTIVE
  The objective of the study was to determine whether blood pressure increases are associated with maternal angiogenic factors in uncomplicated and preeclamptic pregnancies.
  
  
  METHODS
  Associations of blood pressure increases from mid- to late pregnancy with maternal serum concentrations of soluble fms-like tyrosine kinase receptor (sFlt1), soluble endoglin (sEng), and placental growth factor (PlGF) at delivery were analyzed in 43 uncomplicated and 44 preeclamptic pregnancies.
  
  
  RESULTS
  In uncomplicated pregnancies, increases in diastolic and mean arterial pressure were inversely associated with PlGF at delivery and positively associated with sEng and sFlt1/PlGF ratio. There were no significant associations between blood pressure increases and angiogenic factor concentrations in preeclampsia.
  
  
  CONCLUSIONS
  These data suggest that angiogenic factors are involved in blood pressure modulation in normotensive pregnancy and are consistent with the hypothesis that angiogenic balance plays a role in maternal breast cancer risk reduction associated with mid- to late blood pressure increases in uncomplicated pregnancies.
authors: Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
authors: Rebecca
authors: R
authors: Troisi
authors: Kristin
authors: K
authors: Braekke
authors: Nina Kittelsen
authors: NK
authors: Harsem
authors: Marianne
authors: M
authors: Hyer
authors: Robert N
authors: RN
authors: Hoover
authors: Anne Cathrine
authors: AC
authors: Staff
mesh_terms: D000293:Adolescent; D000328:Adult; D043925:Angiogenesis Inducing Agents / Q000032:analysis / Q000097:blood; D042501:Angiogenic Proteins / Q000032:analysis / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D001795:Blood Pressure Determination; D016022:Case-Control Studies; D002585:Cesarean Section / Q000706:statistics & numerical data; D036861:Delivery, Obstetric / Q000379:methods; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000150:complications / Q000175:diagnosis*; D016014:Linear Models; D000072483:Placenta Growth Factor; D011225:Pre-Eclampsia / Q000097:blood* / Q000175:diagnosis; D011247:Pregnancy; D011256:Pregnancy Outcome; D011257:Pregnancy Proteins / Q000097:blood; D011262:Pregnancy Trimester, Second; D011263:Pregnancy Trimester, Third; D011336:Probability; D012016:Reference Values; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D040281:Vascular Endothelial Growth Factor Receptor-1
chemical_list: D043925:Angiogenesis Inducing Agents; D042501:Angiogenic Proteins; D015415:Biomarkers; C000608036:PGF protein, human; D011257:Pregnancy Proteins; D000072483:Placenta Growth Factor; D040281:Vascular Endothelial Growth Factor Receptor-1